A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...

Eli Lilly will seek to have Mounjaro listed on the scheme this year. If successful, it would mean taxpayer subsidies for the ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.81% and ...

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are ...

Eli Lilly moves to defend FDA's tirzepatide shortage resolution amid criticism over supply issues and compounding pharmacy claims.

Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by ...

For a long time, dieting and exercise were the only realistic options for many people who wanted to lose weight, but recent ...

Weight loss is never a cakewalk, and for Mia, it was nothing less than unachievable until she found out about Mounjaro weight ...

Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...

Obesity is more than a cosmetic concern. It’s a chronic disease that can be treated with drugs like semaglutide (Wegovy) and ...

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...